Literature DB >> 24169926

Tardive dystonic syndrome induced by the calcium-channel blocker amlodipine.

Dirk Dressler1.   

Abstract

Identification of drug exposure as a cause for dystonia is important since cessation of the causative agent offers a chance for remission. We describe two patients with a cranial, cervical, pharyngo-laryngeal and axial dystonia, akathisia, breathing dysrhythmias together with depression and anxiety. Both patients were started on the calcium channel blocker (CCB) amlodipine 1 month before symptom onset. They symptoms were non-acute and due to CCBs well-known D2 antagonism; hence they were classified as a tardive dystonic syndrome. Parkinsonism and depression have been described especially for the CCB flunarizine and cinnarizine. Tardive dystonia under CCB has rarely been reported. CCB exposure should be investigated in all dystonias with cranial, cervical, pharyngo-laryngeal and axial manifestations, especially when additional akathisia, Parkinsonism and depression are present. When CCB induction is suspected, CCB cessation may offer a chance for spontaneous remission. Whether CCB exposure can deteriorate, idiopathic dystonia is unclear. Therefore, CCB should best be avoided in patients with dystonia.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24169926     DOI: 10.1007/s00702-013-1108-8

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  7 in total

Review 1.  Calcium channel blockers for neuroleptic-induced tardive dyskinesia.

Authors:  Adib Essali; Hany Deirawan; Karla Soares-Weiser; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2011-11-09

2.  Verapamil and acute dystonia.

Authors:  M A Pina; J R Ara; A Remírez; J Castiella
Journal:  J Clin Pharm Ther       Date:  1998-02       Impact factor: 2.512

Review 3.  Drug-induced parkinsonism: a review of 17 years' experience in a regional pharmacovigilance center in France.

Authors:  Emmanuelle Bondon-Guitton; Santiago Perez-Lloret; Haleh Bagheri; Christine Brefel; Olivier Rascol; Jean-Louis Montastruc
Journal:  Mov Disord       Date:  2011-06-14       Impact factor: 10.338

4.  A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism.

Authors:  A Negrotti; S Calzetti
Journal:  Mov Disord       Date:  1997-01       Impact factor: 10.338

5.  Parkinsonism and other movement disorders in outpatients in chronic use of cinnarizine and flunarizine.

Authors:  Giorgio Fabiani; Paulo C Pastro; Carolina Froehner
Journal:  Arq Neuropsiquiatr       Date:  2004-10-05       Impact factor: 1.420

Review 6.  History of calcium antagonists.

Authors:  A Fleckenstein
Journal:  Circ Res       Date:  1983-02       Impact factor: 17.367

7.  Flunarizine- and cinnarizine-induced extrapyramidal reactions.

Authors:  F Micheli; M F Pardal; M Gatto; M Torres; G Paradiso; I C Parera; R Giannaula
Journal:  Neurology       Date:  1987-05       Impact factor: 9.910

  7 in total
  5 in total

1.  L-type calcium channel blockers and a symptom complex mimicking de Melo-Souza's syndrome.

Authors:  Upinder Kaur; Pritam Das; Indrajeet Singh Gambhir; Sankha Shubhra Chakrabarti
Journal:  Neurol Sci       Date:  2018-12-01       Impact factor: 3.307

2.  Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.

Authors:  Koen Demyttenaere; Johan Detraux; Giorgio Racagni; Kristof Vansteelandt
Journal:  CNS Drugs       Date:  2019-06       Impact factor: 5.749

Review 3.  Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges.

Authors:  Haitham Salem; Caesa Nagpal; Teresa Pigott; Antonio Lucio Teixeira
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

4.  Tardive akathisia related to the anti-hypertensive agent Sevikar-a case report.

Authors:  Men-Ting Hsieh; Pao-Yen Lin; Chia-Jen Tsai; Chiung-Chih Chang; Yu Lee
Journal:  BMC Pharmacol Toxicol       Date:  2017-06-05       Impact factor: 2.483

5.  Pisa syndrome associated with mirtazapine: a case report.

Authors:  Yuji Yamada; Harumasa Takano; Maki Yamada; Naoko Satake; Naotsugu Hirabayashi; Mitsutoshi Okazaki; Kazuyuki Nakagome
Journal:  BMC Pharmacol Toxicol       Date:  2018-12-06       Impact factor: 2.483

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.